prednisone has been researched along with Dysesthesia in 41 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 7.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| "Despite significant effects of melphalan and prednisone in the therapy of systemic AL-amyloidosis, overall prognosis is poor and remission of clinical symptoms cannot generally be expected." | 7.70 | [Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy]. ( Grabensee, B; Heering, P; Hetzel, GR, 1999) |
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 3.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| "Despite significant effects of melphalan and prednisone in the therapy of systemic AL-amyloidosis, overall prognosis is poor and remission of clinical symptoms cannot generally be expected." | 3.70 | [Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy]. ( Grabensee, B; Heering, P; Hetzel, GR, 1999) |
| "Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients)." | 2.65 | A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. ( Falkson, G; Falkson, HC; Glidewell, OJ; Henry, PH; Holland, JF; Leone, LA; Perloff, M; Tormey, DC; Weinberg, VE; Weiss, RB, 1983) |
| "Leprosy is rare within non-endemic countries such as Canada, where cases are almost exclusively imported from endemic regions, often presenting after an incubation period of as many as 20 years." | 1.91 | Leprosy with type 1 reaction in a patient from Ontario, Canada without recent travel misdiagnosed as vasculitic neuropathy: a case report. ( Driedger, M; Roth, V; Teo, I, 2023) |
| "Sudden sensorineural hearing loss (SSHNL) is an emergency in otolaryngology." | 1.35 | Sudden hearing loss as the presenting symptom of systemic sclerosis. ( Deroee, AF; Hojjati, M; Huang, TC; Morita, N, 2009) |
| "Syringes associated with myelitis shared some common features: they developed during the acute phase of myelitis and disappeared after steroids, were all non-communicating cavitations involving the central canal, and occurred in the same spinal segment affected by myelitis." | 1.34 | Pathogenetic role of myelitis for syringomyelia. ( Bergamaschi, R; Bogdanov, EI; Mikhaylov, IM; Moglia, A; Pichiecchio, A; Ravaglia, S, 2007) |
| "Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by symmetrical sclerodermatous skin changes primarily affecting the extremities and histologically, by thickening of the fascia with chronic inflammatory infiltrate containing eosinophils." | 1.34 | Eosinophilic fasciitis in a 57-year-old Japanese-American woman. ( Ambrocio, DU; Uramoto, K, 2007) |
| "Pain is not usually considered a symptom of chronic relapsing demyelinating polyneuropathy." | 1.29 | Upper limb pain in chronic demyelinating polyneuropathy: electrophysiological correlates. ( Brunet, DG; Zochodne, DW, 1994) |
| "Spinal cord compression has been reported in 5% of patients with solid tumors." | 1.29 | [Spinal cord compression as the presenting form of non-Hodgkin's lymphoma]. ( Amigo, ML; Caballero, D; del Cañizo, C; Revilla, R; San Miguel, JF; Sánchez, C, 1995) |
| " The progressive reduction of corticosteroid dosage led rapidly to a distinct improvement, but not to a remission, of symptoms." | 1.28 | Steroid myopathy: clinical and immunohistochemical study of a case. ( Camporeale, FS; Carandente, M; Cioffi, M; Gentile, A; Marolda, M; Orsini, AV; Palma, V, 1991) |
| "Hypereosinophilia was probably idiopathic, however the presence of atypical findings suggested transition to vasculitides or collagen disease." | 1.28 | Peripheral neuropathy associated with hypereosinophilia. ( Dall'Asta, D; Fornaciari, G; Gemignani, F; Guidetti, D; Marbini, A; Ragni, P; Terenziani, S, 1991) |
| "The causes for acroparesthesia during pregnancy are explained by endocrine respectively acromegalic changes." | 1.28 | [Acroparesthesia in the hands of pregnant women]. ( Ilchevski, S, 1989) |
| "Four cases of angioimmunoblastic lymphadenopathy associated to peripheral neuropathy are described." | 1.26 | [Neuropathy in angioimmunoblastic lymphadenopathy (author's transl)]. ( Binet, JL; Brunet, P; De Baecque, C; de Saxce, H; Gray, F; Lyon-Caen, O; Raphael, M, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (29.27) | 18.7374 |
| 1990's | 9 (21.95) | 18.2507 |
| 2000's | 14 (34.15) | 29.6817 |
| 2010's | 5 (12.20) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Driedger, M | 1 |
| Teo, I | 1 |
| Roth, V | 1 |
| Flinn, IW | 1 |
| van der Jagt, R | 1 |
| Kahl, BS | 1 |
| Wood, P | 1 |
| Hawkins, TE | 1 |
| Macdonald, D | 1 |
| Hertzberg, M | 1 |
| Kwan, YL | 1 |
| Simpson, D | 1 |
| Craig, M | 1 |
| Kolibaba, K | 1 |
| Issa, S | 1 |
| Clementi, R | 1 |
| Hallman, DM | 1 |
| Munteanu, M | 1 |
| Chen, L | 1 |
| Burke, JM | 1 |
| Oerlemans, S | 1 |
| Issa, DE | 1 |
| van den Broek, EC | 1 |
| Nijziel, MR | 1 |
| Coebergh, JW | 1 |
| Huijgens, PC | 1 |
| Mols, F | 1 |
| van de Poll-Franse, LV | 1 |
| van Zyl, T | 1 |
| Papakostas, TD | 1 |
| Sobrin, L | 1 |
| Wakamoto, H | 1 |
| Chisaka, A | 1 |
| Inoue, N | 1 |
| Nakano, N | 1 |
| Gernhofer, KJ | 1 |
| Castelino, FV | 1 |
| Wasfy, JH | 1 |
| Collier, D | 1 |
| Siniscalchi, A | 1 |
| Fratoni, S | 1 |
| Santeusanio, G | 1 |
| Del Poeta, G | 1 |
| de Fabritiis, P | 1 |
| Caravita, T | 1 |
| Deroee, AF | 1 |
| Huang, TC | 1 |
| Morita, N | 1 |
| Hojjati, M | 1 |
| Rigamonti, A | 1 |
| Lauria, G | 1 |
| Balgera, R | 1 |
| Agostoni, E | 1 |
| Rath, JJ | 1 |
| Ronday, HK | 1 |
| Wirtz, PW | 1 |
| López-López, J | 1 |
| Estrugo-Devesa, A | 1 |
| Jané-Salas, E | 1 |
| Segura-Egea, JJ | 1 |
| PALLIS, CA | 1 |
| SCOTT, JT | 1 |
| LEES, F | 1 |
| LIVERSEDGE, LA | 1 |
| Hengstman, GJ | 1 |
| Schelhaas, HJ | 1 |
| Zwarts, MJ | 1 |
| Ben Ghorbel, I | 1 |
| Ibnelhadj, Z | 1 |
| Zouari, M | 1 |
| Nagi, S | 1 |
| Khanfir, M | 1 |
| Hentati, F | 1 |
| Houman, MH | 1 |
| Kawakami, T | 1 |
| Soma, Y | 1 |
| Hosaka, E | 1 |
| Mizoguchi, M | 1 |
| Briani, C | 1 |
| Scarlato, M | 1 |
| Pavan, A | 1 |
| Marcolongo, R | 1 |
| Rondinone, R | 1 |
| Adami, F | 1 |
| Ravaglia, S | 1 |
| Bogdanov, EI | 1 |
| Pichiecchio, A | 1 |
| Bergamaschi, R | 1 |
| Moglia, A | 1 |
| Mikhaylov, IM | 1 |
| Ambrocio, DU | 1 |
| Uramoto, K | 1 |
| González Pérez, P | 1 |
| Serrano-Pozo, A | 1 |
| Franco-Macías, E | 1 |
| Montes-Latorre, E | 1 |
| Gómez-Aranda, F | 1 |
| Campos, T | 1 |
| Brunet, P | 1 |
| Binet, JL | 1 |
| de Saxce, H | 1 |
| Gray, F | 1 |
| De Baecque, C | 1 |
| Raphael, M | 1 |
| Lyon-Caen, O | 1 |
| Massey, EW | 1 |
| Tormey, DC | 1 |
| Weinberg, VE | 1 |
| Holland, JF | 1 |
| Weiss, RB | 1 |
| Glidewell, OJ | 1 |
| Perloff, M | 1 |
| Falkson, G | 1 |
| Falkson, HC | 1 |
| Henry, PH | 1 |
| Leone, LA | 1 |
| Kempin, S | 1 |
| Lee, BJ | 1 |
| Thaler, HT | 1 |
| Koziner, B | 1 |
| Hecht, S | 1 |
| Gee, T | 1 |
| Arlin, Z | 1 |
| Little, C | 1 |
| Straus, D | 1 |
| Reich, L | 1 |
| Phillips, E | 1 |
| Al-Mondhiry, H | 1 |
| Dowling, M | 1 |
| Mayer, K | 1 |
| Clarkson, B | 1 |
| Zochodne, DW | 1 |
| Brunet, DG | 1 |
| Vincent, SD | 1 |
| Lilly, GE | 1 |
| Hupp, JR | 1 |
| Amigo, ML | 1 |
| Revilla, R | 1 |
| Sánchez, C | 1 |
| del Cañizo, C | 1 |
| Caballero, D | 1 |
| San Miguel, JF | 1 |
| Lee, JB | 1 |
| Koblenzer, PS | 1 |
| Rayder, R | 1 |
| Brewer, W | 1 |
| Hamilton, R | 1 |
| Kumar, A | 1 |
| Sebes, J | 1 |
| Carbone, L | 1 |
| Hetzel, GR | 1 |
| Heering, P | 1 |
| Grabensee, B | 1 |
| Ferriby, D | 1 |
| Stojkovic, T | 1 |
| De Seze, J | 1 |
| Hurtevent, JF | 1 |
| Vermersch, P | 1 |
| Ballabio, CB | 1 |
| Miller, RG | 1 |
| Marolda, M | 1 |
| Palma, V | 1 |
| Camporeale, FS | 1 |
| Carandente, M | 1 |
| Cioffi, M | 1 |
| Orsini, AV | 1 |
| Gentile, A | 1 |
| Guidetti, D | 1 |
| Gemignani, F | 1 |
| Terenziani, S | 1 |
| Ragni, P | 1 |
| Fornaciari, G | 1 |
| Dall'Asta, D | 1 |
| Marbini, A | 1 |
| Ilchevski, S | 1 |
| Jehn, U | 1 |
| Mezger, J | 1 |
| Rodriguez, V | 1 |
| Hart, JS | 1 |
| Freireich, EJ | 1 |
| Bodey, GP | 1 |
| McCredie, KB | 1 |
| Whitecar, JP | 1 |
| Coltman, CA | 1 |
| Stein, RS | 1 |
| Moran, EM | 1 |
| Desser, RK | 1 |
| Miller, JB | 1 |
| Golomb, HM | 1 |
| Ultmann, JE | 1 |
| Beckman, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHO[NCT00877006] | Phase 3 | 447 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis[NCT04943302] | Phase 2 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to PI left institution. Study not moving forward in her absence.) | ||
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). This outcome reports the global health status on a scale of 0-100 with a high score for the global health status/QOL represents a high quality of life. (NCT00877006)
Timeframe: Day 1 (prior to treatment), 32 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Bendamustine and Rituximab (BR) | 3.6 |
| R-CHOP/R-CVP | -5.1 |
DOR was defined as the time from first response (CR or PR) to disease progression or relapse, or death due to any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 26.5 |
| R-CHOP/R-CVP | 32.1 |
"EFS was defined as the time from randomization to treatment failure, disease progression or relapse, other malignancies, or death from any cause, whichever occurred first.~Treatment failure was defined as failure to achieve a CR or PR after 6 cycles of treatment. If a patient failed to achieve CR or PR by the time of data analysis or early withdrawal, the treatment failure date was set at 126 days (6 cycles of treatment) after randomization or the new anticancer treatment date, whichever is earlier." (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 31.8 |
| R-CHOP/R-CVP | 32.6 |
PFS was defined as the time from randomization to disease progression or relapse, or death from any cause, whichever occurred first. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 31.8 |
| R-CHOP/R-CVP | 33.4 |
OS was defined as the time from randomization to death from any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)
| Intervention | months (Median) |
|---|---|
| Bendamustine and Rituximab (BR) | 65.0 |
| R-CHOP/R-CVP | 64.1 |
"Relapsed disease (after CR) and progressive disease (PD) (after PR or SD):~Lymph nodes were considered abnormal if the long axis was greater than 1.5 cm. Lymph nodes with a long axis of 1.1 to 1.5 cm were considered abnormal if its short axis was greater than 1.0 cm.~In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT require histologic confirmation.~>= 50% increase from nadir in sum of the products of the greatest diameters (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must have increased by 2: 50% and to a size of 1.5 cm by 1.5 cm, or more than 1.5 cm in the long axis~other conditions as specified in the protocol" (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine and Rituximab (BR) | 36 |
| R-CHOP/R-CVP | 30 |
CR=complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, if present pretherapy; protocol-specified positron emission tomography (PET) scan assessment criteria; (if the spleen and/or liver were enlarged on the basis of physical examination and/or anatomic imaging before treatment) the liver and/or spleen were considered normal size on physical examination and by anatomic imaging after therapy, with disappearance of all nodules related to lymphoma; (if the bone marrow was involved by lymphoma before treatment) the infiltrate must have cleared on subsequent bone marrow biopsies. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Bendamustine and Rituximab (BR) | 31 |
| R-CHOP/R-CVP | 25 |
Overall Response=participants with Complete Remission (CR) + those with Partial Remission (PR). CR=see Outcome Measure 1 for details. PR= at least a 50% decrease in the sum of the product of the greatest diameters (SPD) of up to 6 of the largest dominant nodes/masses; at least a 50% decrease in the SPD of hepatic and splenic nodules in their greatest transverse diameter; no increase in the size of the liver, spleen, and other nodes; no measurable disease in organs other than the liver or spleen; no new sites of disease; protocol-specified PET scan and bone marrow criteria. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Bendamustine and Rituximab (BR) | 97 |
| R-CHOP/R-CVP | 91 |
(NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Heart Rate >=120 and ↑ >=15 bpm | Heart Rate <=50 and ↓ >=15 bpm | Systolic Blood Pressure(BP) >=180 and ↑ >=20 mm Hg | Systolic BP <=90 and ↓ >=20 mm Hg | Diastolic BP >=105 and ↑ from Baseline >=15 mm Hg | Diastolic BP <=50 and ↓ from Baseline >=15 mm Hg | |
| Bendamustine and Rituximab (BR) | 0 | 2 | 2 | 6 | 1 | 2 |
| R-CHOP/R-CVP | 1 | 2 | 2 | 2 | 2 | 2 |
Participants' ECOG Performance Status was evaluated at the end of treatment as improved, stayed the same, or worsened from baseline (see Baseline Characteristics for ECOG Performance Status). (NCT00877006)
Timeframe: Week 32
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Stayed the Same | Worsened | |
| Bendamustine/Rituximab | 32 | 153 | 34 |
| R-CHOP/R-CVP | 28 | 141 | 42 |
AE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. An AE can, therefore, be any unfavorable and unintended physical sign, symptom, or laboratory parameter that develops or worsens in severity during the course of the study, or significant worsening of the disease under study (or any concurrent disease), whether or not considered related to the study drug. AEs were graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). SAE=an adverse event occurring at any dose that results in: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity (a substantial disruption of one's ability to conduct normal life functions), a congenital anomaly/birth defect, or other important medical event. (NCT00877006)
Timeframe: 32 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any AE | Severe AEs (grades 3, 4, 5) | Treatment-related AEs | Deaths | SAEs | Withdrawn due to AEs | |
| Bendamustine and Rituximab (BR) | 221 | 130 | 209 | 12 | 60 | 10 |
| R-CHOP/R-CVP | 213 | 127 | NA | 9 | 49 | 3 |
Death is due to any cause. Data are broken out by patients who died within 30 days of the last dose of study medications, and those who died greater than 30 days of the last dose of study medications. (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| All Deaths | Deaths within 30 days of study treatment | Deaths greater than 30 days of study treatment | |
| Bendamustine and Rituximab (BR) | 40 | 2 | 38 |
| R-CHOP/R-CVP | 32 | 1 | 31 |
Participants were weighed at Baseline and at Endpoint (Week 32); those participants with an increase or decrease of >=10% were considered potentially clinically significant. (NCT00877006)
Timeframe: Baseline, Week 32
| Intervention | participants (Number) | |
|---|---|---|
| Increase >=10% | Decrease >=10% | |
| Bendamustine and Rituximab (BR) | 8 | 18 |
| R-CHOP/R-CVP | 5 | 8 |
(NCT00877006)
Timeframe: 32 weeks
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psycholeptics | Sex Hormones and Modulators of the Genital System | Stomatological Preparations | Throat Preparations | Thyroid Therapy | Topical Preparations for Join and Muscular Pain | Unspecified Herbal | Urologicals | Vaccines | Vasoprotectives | Vitamins | |
| Bendamustine and Rituximab (BR) | 69 | 6 | 23 | 3 | 3 | 1 | 3 | 5 | 11 | 1 | 16 |
| R-CHOP/R-CVP | 74 | 4 | 29 | 2 | 1 | 2 | 5 | 4 | 11 | 8 | 21 |
(NCT00877006)
Timeframe: prior to start of treatment
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psycholeptics | Sex Hormones and Modulators of the Genital System | Stomatological Preparations | Throat Preparations | Thyroid Therapy | Topical Products for Join and Muscular Pain | Unspecified Herbal | Urologicals | Vaccines | Vasoprotectives | Vitamins | |
| Bendamustine and Rituximab (BR) | 57 | 11 | 0 | 0 | 16 | 1 | 10 | 20 | 2 | 0 | 70 |
| R-CHOP/R-CVP | 59 | 12 | 0 | 0 | 17 | 0 | 10 | 11 | 7 | 0 | 61 |
Clinical laboratory data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for serum chemistry test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and laboratory test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albumin: Grade 1 | Albumin: Grade 2 | Albumin: Grade 3 | Albumin: Grade 4 | Albumin: Grades 1-4 | Alkaline Phosphatase: Grade 1 | Alkaline Phosphatase: Grade 2 | Alkaline Phosphatase: Grade 3 | Alkaline Phosphatase: Grade 4 | Alkaline Phosphatase: Grades 1-4 | Creatinine: Grade 1 | Creatinine: Grade 2 | Creatinine: Grade 3 | Creatinine: Grade 4 | Creatinine: Grades 1-4 | Gamma-glutamyl transferase: Grade 1 | Gamma-glutamyl transferase: Grade 2 | Gamma-glutamyl transferase: Grade 3 | Gamma-glutamyl transferase: Grade 4 | Gamma-glutamyl transferase: Grades 1-4 | Hypercalcemia: Grade 1 | Hypercalcemia: Grade 2 | Hypercalcemia: Grade 3 | Hypercalcemia: Grade 4 | Hypercalcemia: Grades 1-4 | Hyperglycemia: Grade 1 | Hyperglycemia: Grade 2 | Hyperglycemia: Grade 3 | Hyperglycemia: Grade 4 | Hyperglycemia: Grades 1-4 | Hyperkalemia: Grade 1 | Hyperkalemia: Grade 2 | Hyperkalemia: Grade 3 | Hyperkalemia: Grade 4 | Hyperkalemia: Grades 1-4 | Hypernatremia: Grade 1 | Hypernatremia: Grade 2 | Hypernatremia: Grade 3 | Hypernatremia: Grade 4 | Hypernatremia: Grades 1-4 | Hypocalcemia: Grade 1 | Hypocalcemia: Grade 2 | Hypocalcemia: Grade 3 | Hypocalcemia: Grade 4 | Hypocalcemia: Grades 1-4 | Hypoglycemia: Grade 1 | Hypoglycemia: Grade 2 | Hypoglycemia: Grade 3 | Hypoglycemia: Grade 4 | Hypoglycemia: Grades 1-4 | Hypokalemia: Grade 1 | Hypokalemia: Grade 2 | Hypokalemia: Grade 3 | Hypokalemia: Grade 4 | Hypokalemia: Grades 1-4 | Hyponatremia: Grade 1 | Hyponatremia: Grade 2 | Hyponatremia: Grade 3 | Hyponatremia: Grade 4 | Hyponatremia: Grades 1-4 | Magnesium: Grade 1 | Magnesium: Grade 2 | Magnesium: Grade 3 | Magnesium: Grade 4 | Magnesium: Grades 1-4 | Phosphorus: Grade 1 | Phosphorus: Grade 2 | Phosphorus: Grade 3 | Phosphorus: Grade 4 | Phosphorus: Grades 1-4 | Aspartate Aminotransferase: Grade 1 | Aspartate Aminotransferase: Grade 2 | Aspartate Aminotransferase: Grade 3 | Aspartate Aminotransferase: Grade 4 | Aspartate Aminotransferase: Grades 1-4 | Alanine Aminotransferase: Grade 1 | Alanine Aminotransferase: Grade 2 | Alanine Aminotransferase: Grade 3 | Alanine Aminotransferase: Grade 4 | Alanine Aminotransferase: Grades 1-4 | Total Bilirubin: Grade 1 | Total Bilirubin: Grade 2 | Total Bilirubin: Grade 3 | Total Bilirubin: Grade 4 | Total Bilirubin: Grades 1-4 | Uric Acid: Grade 1 | Uric Acid: Grade 2 | Uric Acid: Grade 3 | Uric Acid: Grade 4 | Uric Acid: Grades 1-4 | |
| Bendamustine and Rituximab (BR) | 33 | 14 | 3 | 0 | 50 | 41 | 1 | 0 | 0 | 42 | 19 | 3 | 1 | 0 | 23 | 31 | 18 | 3 | 0 | 52 | 6 | 0 | 1 | 0 | 7 | 94 | 20 | 15 | 0 | 129 | 7 | 3 | 1 | 0 | 11 | 8 | 0 | 0 | 0 | 8 | 36 | 8 | 1 | 3 | 48 | 15 | 1 | 0 | 0 | 16 | 18 | 0 | 0 | 0 | 18 | 40 | 0 | 0 | 0 | 40 | 46 | 0 | 0 | 0 | 46 | 7 | 25 | 3 | 0 | 35 | 42 | 2 | 1 | 0 | 45 | 46 | 6 | 2 | 0 | 54 | 14 | 1 | 0 | 0 | 15 | 41 | 0 | 0 | 1 | 42 |
| R-CHOP/R-CVP | 44 | 13 | 0 | 0 | 57 | 25 | 3 | 0 | 0 | 28 | 25 | 1 | 0 | 0 | 26 | 37 | 10 | 6 | 0 | 53 | 6 | 0 | 0 | 0 | 6 | 74 | 34 | 15 | 1 | 124 | 8 | 1 | 0 | 0 | 9 | 10 | 0 | 0 | 0 | 10 | 28 | 6 | 0 | 0 | 34 | 10 | 0 | 0 | 0 | 10 | 16 | 0 | 1 | 0 | 17 | 28 | 0 | 5 | 0 | 33 | 44 | 1 | 1 | 0 | 46 | 5 | 22 | 3 | 1 | 31 | 32 | 2 | 1 | 0 | 35 | 38 | 3 | 1 | 0 | 42 | 7 | 0 | 0 | 0 | 7 | 42 | 0 | 0 | 0 | 42 |
Hematology test data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for hematology test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and hematology test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, weekly during treatment, and at the end-of-treatment visit)
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absolute Neutrophil Count: Grade 1 | Absolute Neutrophil Count: Grade 2 | Absolute Neutrophil Count: Grade 3 | Absolute Neutrophil Count: Grade 4 | Absolute Neutrophil Count: Grades 1-4 | Hemoglobin: Grade 1 | Hemoglobin: Grade 2 | Hemoglobin: Grade 3 | Hemoglobin: Grade 4 | Hemoglobin: Grades 1-4 | Lymphocytes Absolute: Grade 1 | Lymphocytes Absolute: Grade 2 | Lymphocytes Absolute: Grade 3 | Lymphocytes Absolute: Grade 4 | Lymphocytes Absolute: Grades 1-4 | Platelets: Grade 1 | Platelets: Grade 2 | Platelets: Grade 3 | Platelets: Grade 4 | Platelets: Grades 1-4 | White Blood Cells: Grade 1 | White Blood Cells: Grade 2 | White Blood Cells: Grade 3 | White Blood Cells: Grade 4 | White Blood Cells: Grades 1-4 | |
| Bendamustine and Rituximab (BR) | 22 | 51 | 48 | 50 | 171 | 129 | 42 | 5 | 1 | 177 | 1 | 5 | 54 | 83 | 143 | 106 | 14 | 9 | 7 | 136 | 41 | 79 | 65 | 19 | 204 |
| R-CHOP/R-CVP | 14 | 20 | 47 | 104 | 185 | 129 | 51 | 7 | 2 | 189 | 6 | 55 | 55 | 9 | 125 | 72 | 14 | 7 | 8 | 101 | 22 | 49 | 89 | 27 | 187 |
2 reviews available for prednisone and Dysesthesia
| Article | Year |
|---|---|
Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; | 1982 |
Neuropathies and myopathies complicating HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Action Potentials; Adult; Antiviral Agents; Azathioprine; Combin | 1991 |
3 trials available for prednisone and Dysesthesia
| Article | Year |
|---|---|
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2014 |
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; BCG Vaccine; Breast Neoplasms; | 1983 |
Combination chemotherapy of lymphomas other than Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Drug Therapy, Combination | 1974 |
36 other studies available for prednisone and Dysesthesia
| Article | Year |
|---|---|
Leprosy with type 1 reaction in a patient from Ontario, Canada without recent travel misdiagnosed as vasculitic neuropathy: a case report.
Topics: Aged, 80 and over; Arthritis, Rheumatoid; Delayed Diagnosis; Diagnostic Errors; Exanthema; Humans; L | 2023 |
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Vision loss and paresthesias in a young man.
Topics: Acute Disease; Blindness; Cyclophosphamide; Fluorescein Angiography; Glucocorticoids; Humans; Immuno | 2015 |
Childhood multifocal acquired demyelinating sensory and motor neuropathy.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Electromyography; Female; Foot; Hereditary Sensory and | 2008 |
Corticosteroid treatment for symptoms associated with infraorbital nerve dysesthesia/paresthesia.
Topics: Adult; Anti-Inflammatory Agents; Dental Restoration, Permanent; Follow-Up Studies; Glucocorticoids; | 2008 |
A 36-year-old man with paresthesias and a headache.
Topics: Adult; Amlodipine; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Guanine; Headache; He | 2008 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema | 2009 |
Sudden hearing loss as the presenting symptom of systemic sclerosis.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Audiometry; Biopsy; Fatigue; Hearing Loss, | 2009 |
Subacute inflammatory polyradiculopathy associated with Sjögren's syndrome.
Topics: Aged; Disease Progression; Electrodiagnosis; Female; Humans; Immunosuppressive Agents; Magnetic Reso | 2009 |
Acute transverse myelitis in psoriatic arthritis.
Topics: Administration, Oral; Arthritis, Psoriatic; Female; Humans; Injections, Intravenous; Leg; Magnetic R | 2010 |
Inferior alveolar nerve injury resulting from overextension of an endodontic sealer: non-surgical management using the GABA analogue pregabalin.
Topics: Adult; Analgesics; Anti-Inflammatory Agents; Epoxy Resins; Female; Follow-Up Studies; Foreign Bodies | 2012 |
PERIPHERAL NEUROPATHY IN RHEUMATOID ARTHRITIS.
Topics: Agglutination; Angiography; Arteritis; Arthritis; Arthritis, Rheumatoid; Brachial Artery; Classifica | 1965 |
Prednisone in the relief of acroparaesthesiae.
Topics: Disease; Hand; Humans; Paresthesia; Prednisone | 1959 |
Auditory dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Evoked Potentials, Auditory, Brain Stem; Functional L | 2004 |
[Behçet's disease associated with peripheral neuropathy].
Topics: Anti-Inflammatory Agents; Anticonvulsants; Behcet Syndrome; Carbamazepine; Cyclophosphamide; Diarrhe | 2005 |
Churg-Strauss syndrome with cutaneous and neurological manifestations preceding asthma.
Topics: Adult; Asthma; Churg-Strauss Syndrome; Eosinophilia; Erythema; Glucocorticoids; Humans; Immunoglobul | 2006 |
Polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes: not always a POEMS syndrome.
Topics: Cyclosporine; Diagnostic Errors; Eosinophilia; Fasciitis; Hepatomegaly; Humans; Hyperpigmentation; I | 2006 |
Pathogenetic role of myelitis for syringomyelia.
Topics: Adult; Back Pain; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Methotrexate; | 2007 |
Eosinophilic fasciitis in a 57-year-old Japanese-American woman.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diagnosis, Differential; Eosinophilia; Fasciitis | 2007 |
Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma.
Topics: Action Potentials; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; | 2007 |
[Neuropathy in angioimmunoblastic lymphadenopathy (author's transl)].
Topics: Aged; Electromyography; Female; Humans; Hypesthesia; Immunoblastic Lymphadenopathy; Lymph Nodes; Mal | 1981 |
Digitalgia paresthetica with digital neuropathy in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Fingers; Humans; Male; Middle Aged; Neural Conduction; Neuriti | 1983 |
Upper limb pain in chronic demyelinating polyneuropathy: electrophysiological correlates.
Topics: Arm; Demyelinating Diseases; Electric Stimulation; Female; Humans; Leg; Male; Middle Aged; Neurologi | 1994 |
Paresthesia of the mandibular division, trigeminal nerve.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Female; Humans | 1993 |
[Spinal cord compression as the presenting form of non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1995 |
Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report.
Topics: Dermatologic Agents; Drug Administration Schedule; Facial Dermatoses; Female; Fingers; Glucocorticoi | 1998 |
Recurrent fainting, dysesthesia, and impotence.
Topics: Adult; Anti-Inflammatory Agents; Central Nervous System Diseases; Diagnosis, Differential; Erectile | 1999 |
[Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy].
Topics: Adult; Aged; Amyloidosis; Edema; Female; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Ag | 1999 |
[Chronic polyradiculoneuritis disclosing sarcoidosis].
Topics: Brain; Chronic Disease; Combined Modality Therapy; Female; Humans; Immunoglobulins, Intravenous; Imm | 2002 |
[Medical treatment of carpal acroparesthesias].
Topics: Administration, Topical; Anti-Inflammatory Agents; Carpal Tunnel Syndrome; Dexamethasone; Diuretics; | 1975 |
Steroid myopathy: clinical and immunohistochemical study of a case.
Topics: Adult; Creatine; Electromyography; Female; Foot Diseases; Humans; Muscle Hypotonia; Muscular Atrophy | 1991 |
Peripheral neuropathy associated with hypereosinophilia.
Topics: Aged; Eosinophilia; Female; Hand; Humans; Leg; Male; Middle Aged; Neurologic Examination; Paresthesi | 1991 |
[Acroparesthesia in the hands of pregnant women].
Topics: Adult; Female; Hand; Humans; Median Nerve; Nerve Compression Syndromes; Paresthesia; Prednisone; Pre | 1989 |
Treatment of chronic myeloid leukemia blast crisis with vindesine and prednisone.
Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Leukocyt | 1985 |
Pomp combination chemotherapy of adult acute leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Bone Marrow; Digestive System; Evaluation Stu | 1973 |
Complicated rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biopsy; Corticosterone; Diabetes Complications; Eye Manifestations; Female; H | 1968 |